These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

391 related items for PubMed ID: 20094043

  • 1. Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial.
    Aronne LJ, Halseth AE, Burns CM, Miller S, Shen LZ.
    Obesity (Silver Spring); 2010 Sep; 18(9):1739-46. PubMed ID: 20094043
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
    Sramek JJ, Leibowitz MT, Weinstein SP, Rowe ED, Mendel CM, Levy B, McMahon FG, Mullican WS, Toth PD, Cutler NR.
    J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
    [Abstract] [Full Text] [Related]

  • 3. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.
    García-Morales LM, Berber A, Macias-Lara CC, Lucio-Ortiz C, Del-Rio-Navarro BE, Dorantes-Alvárez LM.
    Clin Ther; 2006 May; 28(5):770-82. PubMed ID: 16861099
    [Abstract] [Full Text] [Related]

  • 4. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
    McMahon FG, Weinstein SP, Rowe E, Ernst KR, Johnson F, Fujioka K, Sibutramine in Hypertensives Clinical Study Group.
    J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
    [Abstract] [Full Text] [Related]

  • 5. Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects.
    de Simone G, Romano C, De Caprio C, Contaldo F, Salanitri T, di Luzio Paparatti U, Pasanisi F.
    Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):24-30. PubMed ID: 15871847
    [Abstract] [Full Text] [Related]

  • 6. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
    Sánchez-Reyes L, Fanghänel G, Yamamoto J, Martínez-Rivas L, Campos-Franco E, Berber A.
    Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
    [Abstract] [Full Text] [Related]

  • 7. Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study.
    Hauner H, Meier M, Wendland G, Kurscheid T, Lauterbach K, Study Group SA, SAT Study.
    Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):201-7. PubMed ID: 15127325
    [Abstract] [Full Text] [Related]

  • 8. Antiobesity effects of the beta-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats.
    Roth JD, Trevaskis JL, Wilson J, Lei C, Athanacio J, Mack C, Kesty NC, Coffey T, Weyer C, Parkes DG.
    Int J Obes (Lond); 2008 Aug; 32(8):1201-10. PubMed ID: 18560368
    [Abstract] [Full Text] [Related]

  • 9. Weight loss and quality of life improvement in obese subjects treated with sibutramine: a double-blind randomized multicenter study.
    Di Francesco V, Sacco T, Zamboni M, Bissoli L, Zoico E, Mazzali G, Minniti A, Salanitri T, Cancelli F, Bosello O.
    Ann Nutr Metab; 2007 Aug; 51(1):75-81. PubMed ID: 17356258
    [Abstract] [Full Text] [Related]

  • 10. Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT).
    Sharma AM, Caterson ID, Coutinho W, Finer N, Van Gaal L, Maggioni AP, Torp-Pedersen C, Bacher HP, Shepherd GM, James WP, SCOUT Investigators.
    Diabetes Obes Metab; 2009 Mar; 11(3):239-50. PubMed ID: 18671798
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study.
    Gaciong Z, Placha G.
    J Hum Hypertens; 2005 Sep; 19(9):737-43. PubMed ID: 15905888
    [Abstract] [Full Text] [Related]

  • 12. Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study.
    Mathus-Vliegen EM, Balance Study Group.
    Eur J Clin Nutr; 2005 Aug; 59 Suppl 1():S31-8; discussion S39. PubMed ID: 16052193
    [Abstract] [Full Text] [Related]

  • 13. Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes.
    Kaukua JK, Pekkarinen TA, Rissanen AM.
    Int J Obes Relat Metab Disord; 2004 Apr; 28(4):600-5. PubMed ID: 14770192
    [Abstract] [Full Text] [Related]

  • 14. [A randomized, double-blind, placebo-controlled, multicenter study on sibutramine in over-weighted and obese subjects].
    Zhao Y, Wang X, Yan Z.
    Zhonghua Yu Fang Yi Xue Za Zhi; 2001 Sep; 35(5):329-32. PubMed ID: 11769634
    [Abstract] [Full Text] [Related]

  • 15. Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia.
    Dujovne CA, Zavoral JH, Rowe E, Mendel CM, Silbutramine Study Group.
    Am Heart J; 2001 Sep; 142(3):489-97. PubMed ID: 11526363
    [Abstract] [Full Text] [Related]

  • 16. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial.
    Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Arnold ME, Steinberg CM.
    Obes Res; 2000 Sep; 8(6):431-7. PubMed ID: 11011909
    [Abstract] [Full Text] [Related]

  • 17. Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial.
    Caterson ID, Finer N, Coutinho W, Van Gaal LF, Maggioni AP, Torp-Pedersen C, Sharma AM, Legler UF, Shepherd GM, Rode RA, Perdok RJ, Renz CL, James WP, SCOUT Investigators.
    Diabetes Obes Metab; 2012 Jun; 14(6):523-30. PubMed ID: 22192338
    [Abstract] [Full Text] [Related]

  • 18. Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over.
    Fanghänel G, Cortinas L, Sánchez-Reyes L, Berber A.
    Int J Obes Relat Metab Disord; 2001 May; 25(5):741-7. PubMed ID: 11360159
    [Abstract] [Full Text] [Related]

  • 19. Long-term weight loss with sibutramine: a randomized controlled trial.
    Wirth A, Krause J.
    JAMA; 2001 Sep 19; 286(11):1331-9. PubMed ID: 11560538
    [Abstract] [Full Text] [Related]

  • 20. Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population.
    Cuellar GE, Ruiz AM, Monsalve MC, Berber A.
    Obes Res; 2000 Jan 19; 8(1):71-82. PubMed ID: 10678261
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.